HCWB is trading 22.7% down today at $2.02 after the company announced it has terminated an exclusive worldwide license agreement with Wugen to regain full ex vivo rights to immunotherapeutic molecules HCW9201 and HCW9206.
- The decision allows HCW Biologics to take back control of its pipeline strategy and explore alternative future partnering options for these molecules.
- Today's sharp decline follows a significant multi-day rally after earnings, suggesting the move is partially driven by profit-taking and investor repositioning.
- The market is currently reassessing the company's strategic direction and commercialization path following the termination of the Wugen partnership.